Core Insights - Edwards Lifesciences is set to announce its operating results for Q3 2025 on October 30, 2025, followed by a conference call to discuss these results [1][2]. Company Overview - Edwards Lifesciences is recognized as a leading global company in structural heart innovation, focusing on improving patient lives through advanced technologies and partnerships with healthcare stakeholders [3]. Financial Activities - The company has executed an accelerated share repurchase agreement to buy back $500 million of its common stock, bringing the total repurchased shares in 2025 to over $800 million [8]. Regulatory Developments - The U.S. Federal Trade Commission (FTC) has moved to block Edwards Lifesciences' proposed acquisition of JenaValve Technology, which the company believes will limit treatment options for patients with aortic regurgitation [9].

Core Points - Marvell Technology, Inc. has authorized a new $5 billion stock repurchase program, building on its commitment to return capital to stockholders [1][2] - The company has approximately $2 billion remaining under its prior repurchase authorization and has repurchased $300 million of common stock in the current quarter [2] - Marvell has entered into an accelerated share repurchase (ASR) agreement to repurchase an additional $1 billion of its common stock [2][3] - CEO Matt Murphy emphasized the company's confidence in its business and stock value, highlighting sustained revenue and cash flow growth [3] Financial Overview - The new stock repurchase program is part of Marvell's strategy to enhance shareholder value [1][2] - The total amount repurchased in the current quarter, including the ASR, amounts to $1.3 billion [2] Upcoming Events - Marvell's Chairman and CEO will participate in a fireside chat hosted by JP Morgan on September 24, 2025, at 10 AM Pacific Time [3][4]

Core Viewpoint - Collegium Pharmaceutical, Inc. has initiated an Accelerated Share Repurchase (ASR) agreement to repurchase $25 million of its common stock as part of a broader $150 million share repurchase program, reflecting a strategic approach to capital allocation while driving revenue growth and returning capital to shareholders [1][2]. Group 1: Financial Performance - In the first quarter of 2025, Collegium reported a 23% year-over-year revenue growth, attributed to strong sales from its pain management portfolio and significant contributions from its ADHD medication, Jornay PM® [2]. - The ASR agreement will initially deliver 692,281 shares to Collegium, based on a closing stock price of $28.89 on May 9, 2025, which represents approximately 80% of the total shares expected to be repurchased [2]. Group 2: Strategic Initiatives - The Board of Directors authorized the $25 million ASR as part of a disciplined capital allocation strategy aimed at sustaining revenue growth while also returning capital to shareholders [2]. - Collegium's strategy includes expanding its commercial portfolio with Jornay PM as a key growth driver and investing in business development while managing debt and share repurchases [2][3]. Group 3: Company Overview - Collegium Pharmaceutical is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, with a strong portfolio in pain management and a recent entry into neuropsychiatry through the acquisition of Jornay PM [3].